Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

The state attorney general has started cracking down on medical spas marketing unapproved versions of popular weight-loss ...

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for weight loss, and major food conglomerates are trying to cater to their ...

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like ...

Ozempic was originally approved to treat people with Type 2 diabetes, but demand has surged because of the drug’s weight-loss ...

Compounding pharmacies in the Phoenix area and nationwide sell versions of popular weight loss drugs at a cheaper rate but ...

Compounding pharmacies make their own versions of weight loss drugs at a fraction of the price but there are some drawbacks.

Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?

Her departure comes as the snacks maker faces challenges including higher cocoa costs, inflation that has curtailed product ...